Phase 2A/B Efficacy and Safety of Dabogratinib in Participants With Low Grade Upper Tract Urothelial Carcinoma
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorTyra Biosciences, Inc
About this trial
A Phase 2A/B study of Dabogratinib (TYRA-300) in Low Grade Upper Tract Urothelial Carcinoma
Eligibility criteria
Qualifiers
Participants ≥ 18 years of age at the time of informed consent and willing and able to comply with all required study procedures
Confirmed LOW RISK LG UTUC (both favorable and unfavorable) per AUA
At least 5mm of marker lesion left behind
Participants must have previous genomic report or archival/fresh tissue in addition to urine sample for retrospective genomic testing
Disqualifiers
Evidence or any features of high grade (HG) UTUC
History of carcinoma in situ (CIS)
History of prostatic urethral involvement
Current or previous history of muscle invasive bladder cancer
Trial design
Treatments tested in this trial
- Dabogratinib (TYRA-300) 60mg
- Dabogratinib (TYRA-300) 80mg
- Dabogratinib (TYRA-300) TBD
Treatment groups
230 Participants
are divided into 3 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov